ActRIIB

ActRIIB is the highest-affinity type II receptor in the TGF-β superfamily and the primary gatekeeper for myostatin, activin A, activin B, GDF-11, and several other ligands that suppress muscle mass, suppress erythropoiesis, and drive cachexia. Pan-ACVR2B blockade produces more muscle hypertrophy than myostatin-selective inhibition alone - because activin A uses the same receptor. Every scaffold targeting muscle wasting, anemia of chronic disease, or cancer cachexia routes through this card.

ActRIIB (chromosome 3p22.2) is a single-pass transmembrane serine/threonine kinase: a cysteine-rich extracellular domain (~three-finger fold, four invariant disulfide bonds) that binds ligand first, a short transmembrane helix, and a constitutively active intracellular kinase domain with a longer C-terminal extension than the ACVR2A paralog. Ligand engagement at the extracellular "concave knuckle" epitope is the first step; this recruits two type I receptors (ALK4 or ALK7) to complete the heterotetrameric complex. The type II kinase phosphorylates the type I GS domain, activating it to phosphorylate Smad2/3 → Smad4 → nuclear translocation → suppression of muscle anabolic genes and MyoD targets. Non-Smad routes (MAPK/ERK, PI3K/Akt) run in parallel in cancer and fibrotic contexts. Follistatin, GASP-1, and the prodomain of myostatin are the endogenous extracellular antagonists; Smad7 is the intracellular brake.

Luspatercept (ACE-536) - an ActRIIA/B-Fc fusion that traps ligands to relieve late-stage erythroid suppression - is FDA-approved for myelodysplastic syndrome anemia (2019) and beta-thalassemia (2020). Sotatercept (ACE-011, also an ActRIIA-Fc trap) is approved for pulmonary arterial hypertension (2023). Bimagrumab, an anti-ACVR2B monoclonal antibody, increased lean mass and muscle volume in Phase 2 trials for inclusion body myositis and cancer cachexia but is not approved; it also showed fat reduction in obesity trials. Soluble ACVR2B-Fc fusions enhance muscle force in Duchenne MD preclinical models, though vascular side effects (telangiectasia) have limited their therapeutic window. No small molecule targeting ACVR2B extracellular domain is approved. For peptide research, the tractable recipes are: propeptide-mimetic scaffolds that compete with endogenous prodomain release to maintain ligand latency; follistatin-domain fragments engineered for ACVR2B selectivity over ACVR2A; cyclic peptides targeting the extracellular concave-knuckle binding interface to selectively block myostatin/GDF-11 while sparing activin B (which mediates FSH release). The Smad2/3-biased versus Smad1/5/8-biased signaling split is the key fork: scaffolds that shift receptor complex composition from ALK4/7 (Smad2/3) toward ALK2 (Smad1/5/8) may unlock bone-anabolic effects without muscle catabolism.